Abstract
Serial CA125 measurements in 169 patients with epithelial ovarian carcinoma were obtained. Changes in serum CA125 measurements are shown to reflect changes in clinical status. For patients with macroscopic disease receiving chemotherapy, the sensitivity and specificity for predicting response are shown to be 95% and 86% respectively. For patients with no known disease, the sensitivity and specificity for detecting relapse are shown to be 86% and 91% respectively. The clinical correlates with the level of serum CA125 were examined and the most important is shown to be amount of residual disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hawkins, R., Roberts, K., Wiltshaw, E. et al. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 60, 634–637 (1989). https://doi.org/10.1038/bjc.1989.329
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.329
This article is cited by
-
An Audit on the Role of PET/CT in Recurrent Ovarian Cancer in a Tertiary Care Centre
Indian Journal of Gynecologic Oncology (2016)
-
Ovarian cancer: the duplicity of CA125 measurement
Nature Reviews Clinical Oncology (2010)